6,678 trials
Epilepsy
Primary: Percentage of Subjects With a Treatment Failure — 12.7; 23.4 percentage of subjects
Acne Vulgaris
Primary: Change From Baseline in the Global Assessment of Acne Severity (GAAS) Score by Physician — 2.8; -1.2 score on a scale
Cystic Fibrosis
Primary: Change in FEV1 From Baseline to End of Treatment at Day 168 — 0.08; 0.06 liters
Colorectal Cancer
Primary: Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death — 50.25 percentage of participants
Acne Vulgaris
Primary: Worst Postbaseline Tolerability (Erythema) — 25; 28; 27; 24 participants
Ultrasound · CT Scans · MRIs
Primary: Number of Subjects Who Had Success in Sedation — 0; 2; 0; 0 participants
Hypoxemia
Primary: Effect Site Concentration When Conscious Level Reaches OAAS-3 — 2.3; 2.2; 2.5; 2.2 ug/ml
Pain
Primary: Acute Pain — 1.5; 1.74 units on a scale
Heart Failure · Iron Deficiency Anemia
Primary: Serum Hemoglobin Concentration — 1.2 grams per deciliter
Other Reconstructive Surgery
Primary: Pain Score Measured by Visual Analog Scale — 3.48; 1.67 units on a scale — p=<0.01
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving 28 Joint Disease Activity Score (DAS28) Less Than or Equal to (≤) 3.2 at Week 88 — 82.6; 79.1; 42.6 percentage of participants…
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT) — 81; 70; 75; 88 percentage of participants
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Number of Participants With All Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 282; 28 participants
Myocardial Ischemia
Primary: Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors — 34.2; 17.5 percentage of participants
Nausea · Vomiting
Primary: The Percentage of Participants With No Vomiting - Overall Stage — 77.2; 72.0 Percentage of Participants — p=0.191